Taking Flight: A Look Toward the Current and Future Clinical Trials for Angelman Syndrome
Barb Bailus PhD Hello everyone, in celebration of International Angelman Syndrome Day last week, we are going to take a glance into the future and review sev
Barb Bailus PhD Hello everyone, in celebration of International Angelman Syndrome Day last week, we are going to take a glance into the future and review sev
The purpose of this interview study is to gather information about caregivers’ experiences with Angelman syndrome (AS). Caregivers of patients aged 5 to 17
Summary by Allyson Berent, DVM, DACVIM Angelman syndrome (AS) is caused by loss of the maternally inherited copy of the UBE3A gene. Like most genes, the UBE3
Summary by Allyson Berent, DVM, DACVIM Individuals affected with Angelman syndrome (AS) are known to have limited functional speech and are typically able to
[wpv-autop]In Partnership With Vivint Gives Back, FAST Announces The Mother Of All Contests.[/wpv-autop][wpv-autop] Starting today, February 1, 2017 and runn
[wpv-autop]Effects of the synthetic neurosteroid ganaxolone on seizure activity and behavioral deficits in an Angelman syndrome mouse model.[/wpv-autop][wpv-
By Allyson Berent, DVM, DACVIM At the annual Foundation for Angelman Syndrome Therapeutics (FAST) Global Summit in December, Jodi Cook, Ph.D., Chief Operat
“Of all the childhood genetic neurologic disorders of the brain, Angelman syndrome may be the single best candidate for developing a definitive treatment (
Watch all the news and updates from the Science Summit 9-5pm Friday, December 2 (CST) and
the Education Summit on Saturday December 3, 9-4PM.
written by Allyson Berent, DVM DACVIM When we refer to gene therapy in Angelman Syndrome (AS), we are typically referring to a “viral delivery” or “vir